Thyrocare Technologies Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹240Cr
- +24.4% YoY
- +7.1% QoQ
- Net profit
- ₹51Cr
- +34.2% YoY
- +4.1% QoQ
- Margin
- 32%
- +2 pp YoY
- −2 pp QoQ
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn. Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.
From Thyrocare Technologies Ltd's Q1 FY27 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn.
- Medium-term specialty segment (genomics, allergy) expected to form 15-20% of portfolio within 3-5 years.
- Pathology business grew ~27%; franchisee business grew ~23-27% YoY, reflecting strong volume growth.
- Revenue growth target for the company is conservatively around mid to high teens percentage annually.
- New franchisee additions and field force expansions to support volume growth and market penetration in Tier 3 and 4 cities.
- Emphasis on higher-value, semi-specialized tests expected to improve realization and margins.
2 more points from Thyrocare Technologies Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Thyrocare Technologies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.
- Future capex on specialty testing is expected to be limited, mostly expansion CAPEX if volumes exceed expectations.
- No significant capex anticipated for specialty segment in the next year.
2 more points from Thyrocare Technologies Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Thyrocare Technologies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Thyrocare Technologies Ltd said on order book & pipeline — free account, 30 seconds.
Thyrocare Technologies Ltd — Quarterly revenue & net profit
Thyrocare Technologies Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q1 FY26 | YoY | Q4 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 240 | 193 | +24.4% | 224 | +7.1% |
| Operating profit (EBITDA) | 77 | 58 | +32.8% | 75 | +2.7% |
| Operating margin | 32% | 30% | +2 pp | 34% | -2 pp |
| Profit before tax | 68 | 50 | +36% | 64 | +6.3% |
| Net profit (PAT) | 51 | 38 | +34.2% | 49 | +4.1% |
| EPS (₹) | 3.28 | 2.45 | +33.9% | 2.96 | +10.8% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹271 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Thyrocare Technologies's management said in earlier quarters
Others in Healthcare Services this season
- Aatmaj Health (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
- Asarfi Hospital (Q1 FY27)
Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q
- KMC Speciality (Q1 FY27)
Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…
- 3B Blackbio (Q1 FY27)
Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Thyrocare Technologies Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Thyrocare Technologies Ltd Q1 FY27 results?
Franchisee additions guidance for FY27: 700 in Q1, 500 in Q2, 0 in Q3, 500 in Q4; net additions may be lower due to churn. Thyrocare targets mid- to high-teens percentage growth in franchisee additions for FY27, indicating steady volume growth potential.
What is Thyrocare Technologies Ltd share price analysis?
Thyrocare Technologies Ltd currently shows a below-average growth signal. The stock trades at a P/E of 42.7 with a market cap of ₹7,723 Cr. Investors should review the full earnings analysis for detailed insights.
Is Thyrocare Technologies Ltd planning capital expenditure?
Most investments in specialty diagnostics have already been made, focusing on central labs in Mumbai and Delhi.
Keep Thyrocare Technologies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
